Avalo Therapeutics Inc (AVTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2015 | 12-2014 | 12-2013 | 12-2006 | |
| Cash Flows From Operating Activities | ||||
| Net Income | -10,490 | -16,056 | -13,045 | N/A |
| Depreciation Amortization | 24 | 29 | 20 | N/A |
| Accounts payable and accrued liabilities | -269 | -708 | 818 | N/A |
| Other Working Capital | -385 | -2,650 | 765 | N/A |
| Other Operating Activity | 957 | 3,866 | -44 | 0 |
| Operating Cash Flow | $-10,163 | $-15,518 | $-11,485 | $N/A |
| Cash Flows From Investing Activities | ||||
| PPE Investments | -20 | -20 | -29 | N/A |
| Investing Cash Flow | $-20 | $-20 | $-29 | $N/A |
| Cash Flows From Financing Activities | ||||
| Debt Issued | N/A | 9,640 | N/A | N/A |
| Debt Repayment | -1,812 | N/A | N/A | N/A |
| Common Stock Issued | 23,685 | N/A | N/A | N/A |
| Other Financing Activity | -2,271 | 14,219 | 5,416 | 0 |
| Financing Cash Flow | $19,603 | $23,859 | $5,416 | $N/A |
| Beginning Cash Position | 11,742 | 3,422 | 9,520 | N/A |
| End Cash Position | 21,162 | 11,742 | 3,422 | N/A |
| Net Cash Flow | $9,420 | $8,321 | $-6,098 | $N/A |
| Free Cash Flow | ||||
| Operating Cash Flow | -10,163 | -15,518 | -11,485 | N/A |
| Capital Expenditure | -20 | -20 | -29 | N/A |
| Free Cash Flow | -10,183 | -15,538 | -11,514 | 0 |